An AI-designed drug targeting Parkinson’s has won FDA clearance for human trials, signaling a major shift in how neurological medicines are developed.
An AI-designed drug targeting Parkinson’s has won FDA clearance for human trials, signaling a major shift in how neurological medicines are developed.
